Page 88 - Read Online

Yang et al. Hepatoma Res 2020;6:31 I http://dx.doi.org/10.20517/2394-5079.2019.45 Page 8 of 8

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. World Health Organization. Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c [Last accessed on
18 May 2020]
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus
infection. N Engl J Med 2002;347:975-82.
4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular
carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
5. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, et al.; Italian Association of the Study of the Liver Disease (AISF). Sustained
virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology
2007;45:579-87.
6. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, et al. Impact of peginterferon and ribavirin therapy on
hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7.
7. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, et al.; ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in
patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-28.
8. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, et al.; HCV Research, UK. Impact of direct acting antiviral therapy in
patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64:1224-31.
9. Crespo G, Trota N, Londoño MC, Mauro E, Baliellas C, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant
survival and induces significant changes in waiting list composition. J Hepatol 2018;69:11-7.
10. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
11. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
12. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, et al. High incidence of hepatocellular carcinoma following successful
interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65:1070-1.
13. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic
patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
14. Ravi S, Axley P, Jones D, Kodali S, Simpson H, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting
antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152:911-2.
15. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, et al. Successful interferon-free therapy of chronic hepatitis C virus infection
normalizes natural killer cell function. Gastroenterology 2015;149:190-200.e2.
16. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment
outcome. J Clin Invest 2014;124:3352-63.
17. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis
of hepatocellular carcinoma. Hepatology 2009;49:1571-82.
18. Waring JF, Dumas EO, Abel S, Coakley E, Cohen DE, et al. Serum miR-122 may serve as a biomarker for response to direct acting
antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. J Viral Hepat 2016;23:96-104.
19. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, et al. Levels of cytokines in serum associate